NASDAQ · SNY
Healthcare · Drug Manufacturers - General
$44.82
Down-$0.02 (-0.04%)
Updated Aug 30, 2026, 8:24 AM
SID Score
7.2/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SNY closed at $44.82 after 20 trading sessions, up 4.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $44.93 | $44.96 | $44.65 | $44.82 | 1.36M |
| Aug 27, 2026 | $44.86 | $45.08 | $44.72 | $44.84 | 2.29M |
| Aug 26, 2026 | $46.01 | $46.04 | $45.39 | $45.42 | 1.63M |
| Aug 25, 2026 | $45.73 | $46.05 | $45.57 | $46.02 | 1.24M |
| Aug 24, 2026 | $45.49 | $45.78 | $45.32 | $45.69 | 1.72M |
| Aug 21, 2026 | $45.26 | $46.11 | $45.25 | $45.85 | 1.86M |
| Aug 20, 2026 | $45.65 | $45.74 | $45.06 | $45.15 | 2.6M |
| Aug 19, 2026 | $45.42 | $46.02 | $45.42 | $45.83 | 2.74M |
| Aug 18, 2026 | $45.10 | $45.22 | $44.735 | $44.97 | 3.17M |
| Aug 17, 2026 | $44.00 | $44.42 | $43.82 | $44.41 | 1.93M |
| Aug 14, 2026 | $43.51 | $43.80 | $43.235 | $43.72 | 2.72M |
| Aug 13, 2026 | $43.93 | $44.10 | $43.73 | $43.78 | 2.21M |
| Aug 12, 2026 | $43.49 | $43.78 | $43.34 | $43.71 | 2.93M |
| Aug 11, 2026 | $43.62 | $43.90 | $43.43 | $43.56 | 2.84M |
| Aug 10, 2026 | $43.53 | $43.705 | $43.32 | $43.48 | 3.36M |
| Aug 7, 2026 | $43.57 | $43.865 | $43.34 | $43.46 | 2.77M |
| Aug 6, 2026 | $43.30 | $43.51 | $42.76 | $42.89 | 4.15M |
| Aug 5, 2026 | $43.02 | $43.19 | $42.74 | $42.78 | 2.47M |
| Aug 4, 2026 | $42.77 | $42.90 | $42.54 | $42.68 | 2.28M |
| Aug 3, 2026 | $43.50 | $43.81 | $42.68 | $42.95 | 2.6M |
The latest Smart Investors Daily articles mentioning SNY.
SNY research
Company profile and research snapshot.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Jul 12, 2026 | DAY BY DAY | Sell | — |
| Jul 8, 2026 | BANCO SANTANDER | Outperform | — |
| Jul 1, 2026 | JEFFERIES | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 27, 2026
Corvus Pharmaceuticals has delivered strong soquelitinib data in atopic dermatitis, driving a significant market rally and a robust cash raise. Learn more about CRVS stock here.
ChartMill · Aug 27, 2026
Sanofi ADR (SNY) stands out in the Best Dividend screen with a 4.12% yield and strong profitability, but its health rating is only average. Worth a look.
Benzinga · Aug 24, 2026
Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “quite lethal” amid vaccine policy scrutiny.
Benzinga · Aug 18, 2026
Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved clinical trial limitations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNY.
